Alkeran 50 & SD 50mg Powder / solution for injection

Indication

Treatment of multiple myeloma and ovarian cancer.

Dosage (summary)

The usual adult dose is 0.2 to 0.4 mg/kg body weight, administered intravenously or intramuscularly, depending on the specific condition being treated.

Onset of Action / Duration

Onset of action is typically within 1 to 2 hours, with peak effects occurring within 24 hours.

Special Populations

• Elderly patients may require dose adjustments.
• Patients with renal impairment should be closely monitored and may require dose modifications.

Pregnancy & Breastfeeding

Melphalan is contraindicated during pregnancy and lactation due to potential harm to the fetus and nursing infant.

Key Drug Interactions

• May interact with other myelosuppressive agents, increasing the risk of bone marrow suppression.
• Caution is advised when used with live vaccines.

Contraindications

• Hypersensitivity to melphalan or any of the excipients.
• Severe bone marrow depression.
• Pregnancy and lactation.

Common side effects

• Nausea and vomiting.
• Myelosuppression leading to anemia, leukopenia, and thrombocytopenia.
• Mucositis.
• Fatigue.

Counselling Points

• Advise patients to report any signs of infection, unusual bruising, or bleeding.
• Instruct patients to maintain adequate hydration.
• Discuss potential side effects and the importance of regular blood tests to monitor blood counts.